KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) FCF Margin (2020 - 2023)

AbCellera Biologics (ABCL) has disclosed FCF Margin for 4 consecutive years, with 370.87% as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, FCF Margin fell 45712.0% year-over-year to 370.87%, compared with a TTM value of 2150.17% through Sep 2024, down 201483.0%, and an annual FY2024 reading of 648.4%, down 33065.0% over the prior year.
  • FCF Margin was 370.87% for Q4 2023 at AbCellera Biologics, down from 309.75% in the prior quarter.
  • Across five years, FCF Margin topped out at 526.38% in Q2 2022 and bottomed at 484.31% in Q1 2023.
  • Average FCF Margin over 4 years is 27.53%, with a median of 23.84% recorded in 2021.
  • The sharpest move saw FCF Margin skyrocketed 23891bps in 2021, then plummeted -59895bps in 2023.
  • Year by year, FCF Margin stood at 0.11% in 2020, then plummeted by -17315bps to 18.76% in 2021, then soared by 560bps to 86.25% in 2022, then plummeted by -530bps to 370.87% in 2023.
  • Business Quant data shows FCF Margin for ABCL at 370.87% in Q4 2023, 309.75% in Q3 2023, and 72.57% in Q2 2023.